Vaccitech Virtual KOL Event

January 25, 2022

Management and leading experts will discuss VTP-300, as a key component of a potential functional cure for chronic hepatitis B (CHB) infection, as well as the broader HBV therapeutics landscape.

KOL info:

KOLEvent-Invite-KOLsOnly_6ydbf8.jpg

RSVP Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Vaccitech Plc [VACC] $88 MM MCap
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces CD8+ T cell and anti­body im­mune re­spons­es to treat and pre­vent in­fec­tious dis­eas­es and can­cer. Broad ther­a­peu­tic pipe­line. En­cour­ag­ing Ph1/2 in­ter­im ef­fi­ca­cy da­ta for VTP-300 (HBV func­tio­n­al cure) and VTP-200 (high-risk HPV ther­a­peu­tic) ef­fi­ca­cy da­ta ex­pect­ed 4Q2022. $15M roy­al­ty rev­enue dur­ing Q42021 from As­traZene­ca's com­mer­cial sales of Vaxzevria® (out-li­censed ChA­dOx COVID-19 vaccine) [more in­for­ma­tion]